At a glance
ClinicalIndex Comparison Record- ✓Solid kidney mass (primary RCC or metastasis) amenable to SABR ≤6cm
- ✓Histological or radiological diagnosis of renal tumor
- ✓Inoperable due to high surgical risk or patient declined surgery
- ✕≥5 active metastases
- ✕Systemic therapy (except endocrine therapy) within 60 days prior to SABR
- ✕Prior abdominal radiotherapy with field overlap resulting in excessive kidney doses
- ✕End stage renal failure > stage 4 (KDOQI guidelines)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors
In Brief
A clinical study evaluating Stereotactic Ablative Radiotherapy for Renal Tumor. Currently recruiting, targeting 90 participants across 1 site.
Detailed Summary
Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for surgery, there is great interest in non-surgical alternatives for kidney cancer treatments. This study will investigate the use of Stereotactic Ablative Radiosurgery (SABR) for renal tumors. SABR is a non-invasive alternative, which involves delivery of high doses of radiation to the target, while minimizing the risk of injury to the surrounding organs. Patients will be seen before and end of treatmetn and will be followed at 4 month intervals for up to 2 years. During the follow ups, patients will be asked to complete a quality of life questionnaire and will have standard of care imaging.
Study Details
Timeline
Interventions
Stereotactic Ablative Radiotherapy to renal tumors with a dose of 27.5-40 Gy in 5 fractions.